Tissue Heart Valves Market Poised for Strong Growth Amid Rising Cardiovascular Demand

Tissue Heart Valves Market Overview

The global Tissue Heart Valves Market is witnessing notable growth as the prevalence of valvular heart disorders rises and healthcare providers increasingly adopt advanced valve replacement solutions. DelveInsight estimates that the market was valued at USD 10,743.75 million in 2025 and is expected to reach USD 25,307.93 million by 2034, expanding at a CAGR of 10.08% from 2026 to 2034. The heart valves market is benefiting from increasing cases of aortic stenosis and mitral regurgitation, population aging, and growing utilization of minimally invasive procedures, including transcatheter aortic valve replacement (TAVR).

Tissue Heart Valves Market Driven by Rising Valvular Disease Prevalence

The growing incidence of valvular heart diseases is a major factor contributing to the expansion of the Tissue Heart Valves Market. Aortic stenosis is among the key conditions associated with valve replacement, particularly within aging populations. DelveInsight indicates that aortic stenosis affects nearly 10% of people older than 75 years in industrialized nations, with severe disease occurring in approximately 2–4% of this age group. As more patients progress toward moderate and severe disease, the need for valve replacement procedures and tissue-based technologies continues to increase.

Mitral regurgitation is another condition contributing to demand. According to data referenced by DelveInsight, moderate-to-severe mitral regurgitation becomes increasingly prevalent with advancing age and reaches approximately 6.45% among individuals aged 90 years. Surgical and emerging transcatheter mitral valve replacement procedures frequently rely on bioprosthetic technologies, creating additional opportunities for tissue valve manufacturers.

Tissue Heart Valves Market Expands With Transcatheter Treatment Adoption

The increasing use of minimally invasive cardiovascular interventions is influencing the development of the Tissue Heart Valves Market. TAVR and transcatheter aortic valve implantation have gradually expanded from primarily high-risk surgical patients to selected intermediate- and lower-risk populations. Because these interventions commonly use bioprosthetic tissue valves, increasing procedure volumes are generating additional demand.

Factors such as shorter hospitalization, quicker recovery, and reduced procedural invasiveness compared with traditional open-heart surgery have encouraged the use of transcatheter approaches. At the same time, advancements in valve construction, delivery mechanisms, leaflet technology, and anti-calcification treatments are improving the performance of tissue-based devices. These innovations are particularly important for clinicians seeking better procedural outcomes and enhanced long-term valve durability.

Tissue Heart Valves Market Segmentation Highlights Stented Valve Demand

The Tissue Heart Valves Market is categorized according to valve type, valve position, end user, and geography. Based on type, the market encompasses stented, stentless, and sutureless valves. Stented valves are anticipated to represent the largest portion of the market, with an estimated share of around 75% in 2025. Their established clinical use, structural support, relatively straightforward implantation, and suitability across different procedural settings contribute to their significant market presence.

Stented tissue valves feature biological leaflets attached to a supporting frame, enabling controlled positioning during implantation. Improvements such as low-profile designs, enhanced blood-flow characteristics, anti-calcification technologies, and improved coronary access are helping strengthen their clinical application. In March 2023, Abbott received FDA approval for its Epic Max stented tissue valve for patients with aortic regurgitation or stenosis, reflecting continued innovation within this product category.

Tissue Heart Valves Market Sees Aortic Applications Take the Lead